New Brain Mapping Reveals LM11A-31 Impact on Alzheimer’s Networks

Researchers from Indiana University School of Medicine and PharmatrophiX utilized a novel metabolic brain functional-network mapping technique to re-examine data from a Phase 2a trial involving 159 participants. By analyzing 18F-FDG-PET scans, the team tracked how the brain's metabolic activity shifted over a 26-week period. The results indicate that the drug, which targets the p75 neurotrophin receptor, is associated with dose-dependent improvements in whole-brain connectivity and network efficiency, particularly among those receiving a 400 mg dose.

Paul R. Territo, a professor at Indiana University, noted that Alzheimer's functions as a disease of disrupted systemic communication rather than isolated regional damage. The study suggests that LM11A-31 helps the brain maintain its integrated connectivity, with researchers observing distinct, sex-dependent patterns in how the drug influences these networks. These findings align with previous biomarker data and clinical outcomes, where the drug showed a 50% reduction in the progression of cognitive scores compared to the placebo group. PharmatrophiX is now planning a Phase 2b/3 trial to further validate these effects on long-term patient outcomes.